Literature DB >> 32253281

Workflow patterns and potential for optimization in endovascular stroke treatment across the world: results from a multinational survey.

Johanna Maria Ospel1,2, Mohammed A Almekhlafi3, Bijoy K Menon4, Nima Kashani5, René Chapot6, Jens Fiehler7, Ameer E Hassan8, Dileep Yavagal9, Charles B L M Majoie10, Mahesh V Jayaraman11, Michael D Hill12, Mayank Goyal13.   

Abstract

BACKGROUND: The benefit of endovascular treatment (EVT) is highly time-dependent, and treatment delays reduce patients' chances to achieve a good outcome. In this survey-based study, we aimed to evaluate current in-hospital EVT workflow characteristics across different countries and hospital settings, and to quantify the time-savings that could be achieved by optimizing particular workflow steps.
METHODS: In a multinational survey, neurointerventionalists were asked to provide specific information about EVT workflows in their current working environment. Workflow characteristics were summarized using descriptive statistics and stratified by country and physician characteristics, such as age, career stage, personal and institutional caseload.
RESULTS: Among 248 respondents from 48 countries, pre-notification of the neurointerventional team was used in 70% of cases. The emergency department (ED) and CT scanner, and the CT scanner and neuroangiography suite, were on different floors in 23% and 38%, respectively. Redundant procedures in the ED were often routinely performed, such as chest x-rays (in 6%). General anesthesia was the most frequently used anesthesia protocol for EVT (42%), and an anesthesiologist was available in 82% for this purpose. 52% of the participants used a pre-prepared EVT kit.
CONCLUSION: The current structure of EVT workflows offers possibilities for improvement. While some bottlenecks, such as the spatial department set-up, cannot easily be resolved, pre-notification tools and pre-prepared EVT kits are more straightforward to implement and could help to reduce treatment delays, and thereby improve patient outcomes. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  brain; stroke; thrombectomy

Mesh:

Year:  2020        PMID: 32253281     DOI: 10.1136/neurintsurg-2020-015902

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  4 in total

1.  Impact and prevention of errors in endovascular treatment of unruptured intracranial aneurysms.

Authors:  Johanna Maria Ospel; Nima Kashani; Arnuv Mayank; Petra Cimflova; Manraj Heran; Sachin Pandey; Lissa Peeling; Anil Gopinathan; Demetrius Lopes; Naci Kocer; Mayank Goyal
Journal:  Interv Neuroradiol       Date:  2020-07-29       Impact factor: 1.610

2.  Direct to angiography suite approaches for the triage of suspected acute stroke patients: a systematic review and meta-analysis.

Authors:  Alex Brehm; Ioannis Tsogkas; Johanna M Ospel; Christian Appenzeller-Herzog; Junya Aoki; Kazumi Kimura; Johannes A R Pfaff; Markus A Möhlenbruch; Manuel Requena; Marc J Ribo; Amrou Sarraj; Alejandro M Spiotta; Peter Sporns; Marios-Nikos Psychogios
Journal:  Ther Adv Neurol Disord       Date:  2022-03-02       Impact factor: 6.570

3.  Worldwide anaesthesia use during endovascular treatment for medium vessel occlusion stroke.

Authors:  Manon Kappelhof; Johanna M Ospel; Petra Cimflova; Nima Kashani; Nishita Singh; Rosalie McDonough; Arshia Sehgal; Mohammed A Almekhlafi; Jens Fiehler; Michael Chen; Nobuyuki Sakai; Charles Blm Majoie; Mayank Goyal
Journal:  Interv Neuroradiol       Date:  2021-10-19       Impact factor: 1.764

4.  Influence of intravenous alteplase on endovascular treatment decision-making in acute ischemic stroke due to primary medium-vessel occlusion: a case-based survey study.

Authors:  Manon Kappelhof; Johanna Ospel; Nima Kashani; Petra Cimflova; Nishita Singh; Mohammed A Almekhlafi; Bijoy K Menon; Jens Fiehler; Michael Chen; Nobuyuki Sakai; Mayank Goyal
Journal:  J Neurointerv Surg       Date:  2021-05-25       Impact factor: 8.572

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.